Publikace
- Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway2024 | Farmaceutická fakulta v Hradci Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents2017 | Farmaceutická fakulta v Hradci Králové
- Tetrazole regioisomers in the development of nitro group-containing antitubercular agents2015 | Farmaceutická fakulta v Hradci Králové
- Structure-Guided Design of N-Methylpropargylamino- Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease2023 | Farmaceutická fakulta v Hradci Králové, Přírodovědecká fakulta
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity2020 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study2019 | Farmaceutická fakulta v Hradci Králové
Loading network view...